retigabine dihydrochloride  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Name:
    Retigabine dihydrochloride
    Description:
    Retigabine is a potent and selective Kv7 KCNQ M channel modulator enhancer
    Catalog Number:
    R-101
    Price:
    47.0
    Category:
    Small Molecule
    Source:
    Synthetic
    Applications:
    0
    Purity:
    >98%
    Size:
    10 mg
    Format:
    Lyophilized/solid.
    Formula:
    C16H20Cl2FN3O2
    Molecular Weight:
    376.2
    Molecule Name:
    Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate dihydrochloride.
    Buy from Supplier


    Structured Review

    Alomone Labs retigabine dihydrochloride
    Retigabine dihydrochloride
    Retigabine is a potent and selective Kv7 KCNQ M channel modulator enhancer
    https://www.bioz.com/result/retigabine dihydrochloride/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    retigabine dihydrochloride - by Bioz Stars, 2021-09
    90/100 stars

    Images

    1) Product Images from "Pharmacogenetics of KCNQ channel activation in two potassium channelopathy mouse models of epilepsy"

    Article Title: Pharmacogenetics of KCNQ channel activation in two potassium channelopathy mouse models of epilepsy

    Journal: Epilepsia

    doi: 10.1111/epi.13978

    KCNQ activation increases flurothyl-induced seizure latencies in Kcnq1 mice and decreases spontaneous seizure frequency in Kcna1 −/− mice. ( A ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced myoclonic jerks (MJ) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG decreased latency to myoclonic jerk in Kcnq1 A340E/A340E mutant mice ( B ). ( C ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced generalized tonic-clonic seizures (GTCS) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG significantly increased the latency to GTCS in Kcnq1 strain (C57BL/6) mice ( D ). ( E ) EEG traces showing representative spontaneous seizure activity in Kcna1 −/− mice after receiving either VEH or RTG (10 mg·kg −1 ). ( F ) Analysis of spontaneous seizure frequency in Kcna1 −/− mice (n = 6) showed a significant decrease after treatment with 10 mg·kg −1 RTG. ( G ) Average spontaneous seizure durations were similar in Kcna1 −/− mice that exhibited seizures after VEH and 10 mg·kg −1 RTG administration (n = 3). For ( A-D ): *, P ≤ 0.05; **, P ≤ 0.01 (two-tailed unpaired Student’s t -test; n = 6–11 per treatment). For ( F ) and ( G ): *, P ≤ 0.05 (two-tailed paired Student’s t -test). Abbreviations: LT, left temporal; VEH, vehicle; RTG, retigabine; NS, not significant compared to VEH control.
    Figure Legend Snippet: KCNQ activation increases flurothyl-induced seizure latencies in Kcnq1 mice and decreases spontaneous seizure frequency in Kcna1 −/− mice. ( A ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced myoclonic jerks (MJ) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG decreased latency to myoclonic jerk in Kcnq1 A340E/A340E mutant mice ( B ). ( C ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced generalized tonic-clonic seizures (GTCS) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG significantly increased the latency to GTCS in Kcnq1 strain (C57BL/6) mice ( D ). ( E ) EEG traces showing representative spontaneous seizure activity in Kcna1 −/− mice after receiving either VEH or RTG (10 mg·kg −1 ). ( F ) Analysis of spontaneous seizure frequency in Kcna1 −/− mice (n = 6) showed a significant decrease after treatment with 10 mg·kg −1 RTG. ( G ) Average spontaneous seizure durations were similar in Kcna1 −/− mice that exhibited seizures after VEH and 10 mg·kg −1 RTG administration (n = 3). For ( A-D ): *, P ≤ 0.05; **, P ≤ 0.01 (two-tailed unpaired Student’s t -test; n = 6–11 per treatment). For ( F ) and ( G ): *, P ≤ 0.05 (two-tailed paired Student’s t -test). Abbreviations: LT, left temporal; VEH, vehicle; RTG, retigabine; NS, not significant compared to VEH control.

    Techniques Used: Activation Assay, Mouse Assay, Mutagenesis, Activity Assay, Two Tailed Test

    2) Product Images from ""

    Article Title:

    Journal: Molecular Pharmacology

    doi: 10.1124/mol.114.093799

    Comparison of the effects of 10 µ M ML213 on wild-type Kv7.4 and retigabine-insensitive mutant Kv7.4 W242L. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled circles) and after 10-minute treatment with
    Figure Legend Snippet: Comparison of the effects of 10 µ M ML213 on wild-type Kv7.4 and retigabine-insensitive mutant Kv7.4 W242L. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled circles) and after 10-minute treatment with

    Techniques Used: Mutagenesis

    Comparison of effects of 10 µ M ML213 on wild-type Kv7.5 and retigabine-insensitive mutant Kv7.5 W235L. (A) IV curves of normalized steady-state Kv7.5 W235L currents recorded before (control, filled circles) and after 10-minute treatment with 10
    Figure Legend Snippet: Comparison of effects of 10 µ M ML213 on wild-type Kv7.5 and retigabine-insensitive mutant Kv7.5 W235L. (A) IV curves of normalized steady-state Kv7.5 W235L currents recorded before (control, filled circles) and after 10-minute treatment with 10

    Techniques Used: Mutagenesis

    Comparison of effects of 100 µ M ICA-069673 on wild-type Kv7.4, retigabine-insensitive mutant Kv7.4 W242L, and ztz240-insensitive mutant Kv7.4 F143A. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled
    Figure Legend Snippet: Comparison of effects of 100 µ M ICA-069673 on wild-type Kv7.4, retigabine-insensitive mutant Kv7.4 W242L, and ztz240-insensitive mutant Kv7.4 F143A. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled

    Techniques Used: Mutagenesis

    Related Articles

    Concentration Assay:

    Article Title: Pharmacogenetics of KCNQ channel activation in two potassium channelopathy mouse models of epilepsy
    Article Snippet: .. Retigabine dihydrochloride (RTG; Alomone Labs, Jerusalem, Israel) was administered at a concentration of 5, 10, or 20 mg·kg−1 , as specified in the text. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Alomone Labs retigabine dihydrochloride
    KCNQ activation increases flurothyl-induced seizure latencies in Kcnq1 mice and decreases spontaneous seizure frequency in Kcna1 −/− mice. ( A ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced myoclonic jerks (MJ) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG decreased latency to myoclonic jerk in Kcnq1 A340E/A340E mutant mice ( B ). ( C ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced generalized tonic-clonic seizures (GTCS) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG significantly increased the latency to GTCS in Kcnq1 strain (C57BL/6) mice ( D ). ( E ) EEG traces showing representative spontaneous seizure activity in Kcna1 −/− mice after receiving either VEH or RTG (10 mg·kg −1 ). ( F ) Analysis of spontaneous seizure frequency in Kcna1 −/− mice (n = 6) showed a significant decrease after treatment with 10 mg·kg −1 RTG. ( G ) Average spontaneous seizure durations were similar in Kcna1 −/− mice that exhibited seizures after VEH and 10 mg·kg −1 RTG administration (n = 3). For ( A-D ): *, P ≤ 0.05; **, P ≤ 0.01 (two-tailed unpaired Student’s t -test; n = 6–11 per treatment). For ( F ) and ( G ): *, P ≤ 0.05 (two-tailed paired Student’s t -test). Abbreviations: LT, left temporal; VEH, vehicle; RTG, <t>retigabine;</t> NS, not significant compared to VEH control.
    Retigabine Dihydrochloride, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/retigabine dihydrochloride/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    retigabine dihydrochloride - by Bioz Stars, 2021-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    KCNQ activation increases flurothyl-induced seizure latencies in Kcnq1 mice and decreases spontaneous seizure frequency in Kcna1 −/− mice. ( A ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced myoclonic jerks (MJ) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG decreased latency to myoclonic jerk in Kcnq1 A340E/A340E mutant mice ( B ). ( C ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced generalized tonic-clonic seizures (GTCS) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG significantly increased the latency to GTCS in Kcnq1 strain (C57BL/6) mice ( D ). ( E ) EEG traces showing representative spontaneous seizure activity in Kcna1 −/− mice after receiving either VEH or RTG (10 mg·kg −1 ). ( F ) Analysis of spontaneous seizure frequency in Kcna1 −/− mice (n = 6) showed a significant decrease after treatment with 10 mg·kg −1 RTG. ( G ) Average spontaneous seizure durations were similar in Kcna1 −/− mice that exhibited seizures after VEH and 10 mg·kg −1 RTG administration (n = 3). For ( A-D ): *, P ≤ 0.05; **, P ≤ 0.01 (two-tailed unpaired Student’s t -test; n = 6–11 per treatment). For ( F ) and ( G ): *, P ≤ 0.05 (two-tailed paired Student’s t -test). Abbreviations: LT, left temporal; VEH, vehicle; RTG, retigabine; NS, not significant compared to VEH control.

    Journal: Epilepsia

    Article Title: Pharmacogenetics of KCNQ channel activation in two potassium channelopathy mouse models of epilepsy

    doi: 10.1111/epi.13978

    Figure Lengend Snippet: KCNQ activation increases flurothyl-induced seizure latencies in Kcnq1 mice and decreases spontaneous seizure frequency in Kcna1 −/− mice. ( A ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced myoclonic jerks (MJ) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG decreased latency to myoclonic jerk in Kcnq1 A340E/A340E mutant mice ( B ). ( C ) Administration of RTG (10 mg·kg −1 , ip) had no significant effect on latency to flurothyl-induced generalized tonic-clonic seizures (GTCS) in Tac:N:NIHS-BC Kcna1 +/+ and Kcna1 −/− mice. However, RTG significantly increased the latency to GTCS in Kcnq1 strain (C57BL/6) mice ( D ). ( E ) EEG traces showing representative spontaneous seizure activity in Kcna1 −/− mice after receiving either VEH or RTG (10 mg·kg −1 ). ( F ) Analysis of spontaneous seizure frequency in Kcna1 −/− mice (n = 6) showed a significant decrease after treatment with 10 mg·kg −1 RTG. ( G ) Average spontaneous seizure durations were similar in Kcna1 −/− mice that exhibited seizures after VEH and 10 mg·kg −1 RTG administration (n = 3). For ( A-D ): *, P ≤ 0.05; **, P ≤ 0.01 (two-tailed unpaired Student’s t -test; n = 6–11 per treatment). For ( F ) and ( G ): *, P ≤ 0.05 (two-tailed paired Student’s t -test). Abbreviations: LT, left temporal; VEH, vehicle; RTG, retigabine; NS, not significant compared to VEH control.

    Article Snippet: Retigabine dihydrochloride (RTG; Alomone Labs, Jerusalem, Israel) was administered at a concentration of 5, 10, or 20 mg·kg−1 , as specified in the text.

    Techniques: Activation Assay, Mouse Assay, Mutagenesis, Activity Assay, Two Tailed Test

    Comparison of the effects of 10 µ M ML213 on wild-type Kv7.4 and retigabine-insensitive mutant Kv7.4 W242L. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled circles) and after 10-minute treatment with

    Journal: Molecular Pharmacology

    Article Title:

    doi: 10.1124/mol.114.093799

    Figure Lengend Snippet: Comparison of the effects of 10 µ M ML213 on wild-type Kv7.4 and retigabine-insensitive mutant Kv7.4 W242L. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled circles) and after 10-minute treatment with

    Article Snippet: Retigabine dihydrochloride was from Alomone Laboratories (Jerusalem, Israel).

    Techniques: Mutagenesis

    Comparison of effects of 10 µ M ML213 on wild-type Kv7.5 and retigabine-insensitive mutant Kv7.5 W235L. (A) IV curves of normalized steady-state Kv7.5 W235L currents recorded before (control, filled circles) and after 10-minute treatment with 10

    Journal: Molecular Pharmacology

    Article Title:

    doi: 10.1124/mol.114.093799

    Figure Lengend Snippet: Comparison of effects of 10 µ M ML213 on wild-type Kv7.5 and retigabine-insensitive mutant Kv7.5 W235L. (A) IV curves of normalized steady-state Kv7.5 W235L currents recorded before (control, filled circles) and after 10-minute treatment with 10

    Article Snippet: Retigabine dihydrochloride was from Alomone Laboratories (Jerusalem, Israel).

    Techniques: Mutagenesis

    Comparison of effects of 100 µ M ICA-069673 on wild-type Kv7.4, retigabine-insensitive mutant Kv7.4 W242L, and ztz240-insensitive mutant Kv7.4 F143A. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled

    Journal: Molecular Pharmacology

    Article Title:

    doi: 10.1124/mol.114.093799

    Figure Lengend Snippet: Comparison of effects of 100 µ M ICA-069673 on wild-type Kv7.4, retigabine-insensitive mutant Kv7.4 W242L, and ztz240-insensitive mutant Kv7.4 F143A. (A) IV curves of normalized steady-state Kv7.4 W242L currents recorded before (control, filled

    Article Snippet: Retigabine dihydrochloride was from Alomone Laboratories (Jerusalem, Israel).

    Techniques: Mutagenesis